



U.S. Appl. No. 08/921,960  
Attorney Docket No. 037003-0275463

51

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE PATENT APPLICATION OF

Anderson et al.

Group Art Unit: 1644

Application Serial No. 08/921,060

Examiner: R. Schwadron

Filed: August 29, 1997

Title: EX VIVO TREATMENT OF ALLOGENIC AND XENOGENIC DONOR T CELLS CONTAINING COMPOSITIONS (BONE MARROW) USING GP39 ANTAGONISTS AND USE THEREOF

\* \* \* \* \*

ELECTION RESPONSE

RECEIVED

JUN 09 2003

TECH CENTER 1600/2900

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the official communication mailed May 21, 2003, and further in response to the official action [restriction requirement] mailed on December 30, 2002.

Applicants' prior response elected the following species for purposes of examination:

- (a) a method of using the antibody to deplete B cells; and
- (b) the antibody heavy chain of SEQ ID NO. 11.

Applicants now identify claims 24, 31-34, 41, and 42 as readable on the elected species. Applicants note that an antibody used in accordance with the present invention can include both the antibody heavy chain of SEQ ID NO:11 and the antibody light chain of SEQ ID NO:7, for example the C2B8 antibody as disclosed. Thus, applicants believe that claims 30 and 32, which are directed to, *inter alia*, a method of depleting B cells via administration of an antibody having the antibody light chain of SEQ ID NO:7 are also readable on the above-noted elected species.

Applicants respectfully request that the examiner contact the undersigned attorney if there are any remaining questions regarding the required listing of claims.

Respectfully submitted,  
PILLSBURY WINTHROP LLP



---

Thomas A. Cawley, Jr., Ph.D.  
Registration No. 40,944

P.O. Box 10500  
McLean, VA 22102  
(703) 905-2144 Direct Dial  
(703) 905-2500 Facsimile

TAC/JB